Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study.
J Bone Joint Surg Br
; 85(2): 174-7, 2003 Mar.
Article
in En
| MEDLINE
| ID: mdl-12678347
ABSTRACT
We have investigated in a prospective,randomised placebo-controlled study the effect of high-dose aprotinin on blood loss in patients admitted for major surgery (revision arthroplasty of the hip or knee, or for resection of a soft-tissue sarcoma). The mean intraoperative blood loss was reduced from 1957 ml in the control group to 736 ml in the aprotinin group (p = 0.002). The mean requirement for intraoperative homologous blood transfusion in the aprotinin group was 1.4 units (95% CI 0.2 to 2.7) and 3.1 units (95% CI 1.7 to 4.6) in the control group (p = 0.033). The mean length of hospital stay was reduced from 27.8 days in the control group to 17.6 days in the aprotinin group which was not statistically significant. The intraoperative use of aprotinin in major orthopaedic operations significantly reduced blood loss and the required amount of packed cells. It may result in in the length of hospital stay and costs.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hemostatics
/
Aprotinin
/
Blood Loss, Surgical
/
Orthopedic Procedures
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Bone Joint Surg Br
Year:
2003
Document type:
Article
Affiliation country:
Austria